Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
N-acylated derivatives of sulfamethoxazole block Chlamydia fatty acid synthesis and interact with FabF
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Umeå universitet, Teknisk-naturvetenskapliga fakulteten, Kemiska institutionen.
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 61, nr 10, artikel-id e00716-17Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The type II fatty acid synthesis (FASII) pathway is essential for bacterial lipid biosynthesis and continues to be a promising target for novel antibacterial compounds. Recently, it has been demonstrated that Chlamydia is capable of FASII and this pathway is indispensable for Chlamydia growth. Previously, a high-content screen with Chlamydia trachomatis-infected cells was performed, and acylated sulfonamides were identified to be potent growth inhibitors of the bacteria. C. trachomatis strains resistant to acylated sulfonamides were isolated by serial passage of a wild-type strain in the presence of low compound concentrations. Results from whole-genome sequencing of 10 isolates from two independent drug-resistant populations revealed that mutations that accumulated in fabF were predominant. Studies of the interaction between the FabF protein and small molecules showed that acylated sulfonamides directly bind to recombinant FabF in vitro and treatment of C. trachomatis-infected HeLa cells with the compounds leads to a decrease in the synthesis of Chlamydia fatty acids. This work demonstrates the importance of FASII for Chlamydia development and may lead to the development of new antimicrobials.

Ort, förlag, år, upplaga, sidor
American society for microbiology , 2017. Vol. 61, nr 10, artikel-id e00716-17
Nyckelord [en]
Chlamydia trachomatis, FAS, antimicrobial agents, drug targets
Nationell ämneskategori
Mikrobiologi Farmaceutiska vetenskaper
Identifikatorer
URN: urn:nbn:se:umu:diva-140637DOI: 10.1128/AAC.00716-17ISI: 000411481800016Scopus ID: 2-s2.0-85029771373OAI: oai:DiVA.org:umu-140637DiVA, id: diva2:1150353
Tillgänglig från: 2017-10-18 Skapad: 2017-10-18 Senast uppdaterad: 2024-07-02Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Person

Mojica, Sergio A.Salin, OlliSunduru, NareshHedenström, MattiasAndersson, C. DavidNúñez-Otero, CarlosEngström, PatrikElofsson, MikaelGylfe, Åsa

Sök vidare i DiVA

Av författaren/redaktören
Mojica, Sergio A.Salin, OlliSunduru, NareshHedenström, MattiasAndersson, C. DavidNúñez-Otero, CarlosEngström, PatrikElofsson, MikaelGylfe, Åsa
Av organisationen
Institutionen för klinisk mikrobiologiKemiska institutionenInstitutionen för molekylärbiologi (Teknisk-naturvetenskaplig fakultet)Molekylär Infektionsmedicin, Sverige (MIMS)Umeå Centre for Microbial Research (UCMR)
I samma tidskrift
Antimicrobial Agents and Chemotherapy
MikrobiologiFarmaceutiska vetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 757 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf